Property | Value |
?:abstract
|
-
We read with interest the report from Fogarty and colleagues about COVID-19 coagulopathy in Caucasian patients. [1] However, we think that some aspects of this report may deserve further attention. The major concern regards the doses of low-molecular weight heparin (LMWH) used for thromboprophylaxis in this study. Indeed, the Authors report on a weight-adjusted dose of enoxaparin higher than that registered in Europe for the prophylaxis of venous thromboembolism (VTE) in hospitalized acutely ill medical patients.
|
?:creator
|
|
?:doi
|
|
?:doi
|
|
?:journal
|
|
?:license
|
|
?:pdf_json_files
|
-
document_parses/pdf_json/26a4f66248df99823a95cbf05af7ad9cf3e36270.json
|
?:pmc_json_files
|
-
document_parses/pmc_json/PMC7272936.xml.json
|
?:pmcid
|
|
?:pmid
|
|
?:pmid
|
|
?:publication_isRelatedTo_Disease
|
|
?:sha_id
|
|
?:source
|
|
?:title
|
-
More on: ‘COVID‐19 coagulopathy in Caucasian patients’
|
?:type
|
|
?:year
|
|